ERBB2 and metastatic neoplasm: Similarly, whilst anti-HER2 therapies, such as trastuzumab in combination with chemotherapy, have significantly increased overall survival for patients with early and advanced HER2-amplified breast cancer, resistance mechanisms lead to recurrent and metastatic disease [4].